A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

NCT07260305 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: KGX101 injection
DRUG: Envafolimab

Sponsor

Kangabio AUSTRALIA LTD PTY